AUD24.78
3.39% yesterday
Australia, Jun 13, 08:10 am CET
ISIN
AU000000TLX2
Symbol
TLX
Sector
Industry

Telix Pharmaceuticals Stock price

AUD24.78
-0.58 2.29% 1M
+0.25 1.02% 6M
+0.17 0.69% YTD
+8.32 50.55% 1Y
+23.53 1,882.40% 5Y
+24.01 3,118.18% 10Y
+24.01 3,118.18% 20Y
Australia, Closing price Fri, Jun 13 2025
-0.87 3.39%
ISIN
AU000000TLX2
Symbol
TLX
Sector
Industry

Key metrics

Market capitalization AUD8.68b
Enterprise Value AUD8.55b
P/E (TTM) P/E ratio 165.20
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 10.91
P/S ratio (TTM) P/S ratio 11.08
P/B ratio (TTM) P/B ratio 14.60
Revenue growth (TTM) Revenue growth 55.85%
Revenue (TTM) Revenue AUD783.21m
EBIT (operating result TTM) EBIT AUD79.91m
Free Cash Flow (TTM) Free Cash Flow AUD-5.46m
Cash position AUD710.35m
EPS (TTM) EPS AUD0.15
P/E forward 57.66
P/S forward 6.75
EV/Sales forward 6.65
Show more

Is Telix Pharmaceuticals a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

Telix Pharmaceuticals Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Telix Pharmaceuticals forecast:

9x Buy
82%
1x Hold
9%
1x Sell
9%

Analyst Opinions

11 Analysts have issued a Telix Pharmaceuticals forecast:

Buy
82%
Hold
9%
Sell
9%

Financial data from Telix Pharmaceuticals

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
783 783
56% 56%
100%
- Direct Costs 299 299
59% 59%
38%
484 484
54% 54%
62%
- Selling and Administrative Expenses 198 198
19% 19%
25%
- Research and Development Expense 195 195
51% 51%
25%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT 80 80
354% 354%
10%
Net Profit 50 50
858% 858%
6%

In millions AUD.

Don't miss a Thing! We will send you all news about Telix Pharmaceuticals directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Telix Pharmaceuticals Ltd. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.

Head office Australia
CEO Christian Behrenbruch
Employees 423
Founded 2017
Website telixpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today